Rewalk Robotics Ltd (NASDAQ:RWLK) was the target of a significant decline in short interest during the month of December. As of December 31st, there was short interest totalling 467,700 shares, a decline of 5.2% from the December 15th total of 493,600 shares. Currently, 6.9% of the company’s stock are short sold. Based on an average daily trading volume, of 106,100 shares, the short-interest ratio is currently 4.4 days.
RWLK stock traded down $0.28 during trading on Thursday, hitting $2.02. The company had a trading volume of 130,282 shares, compared to its average volume of 70,031. The business has a 50-day moving average of $2.39 and a 200-day moving average of $3.03. Rewalk Robotics has a one year low of $1.85 and a one year high of $10.08. The stock has a market cap of $16.81 million, a PE ratio of -0.14 and a beta of 1.50. The company has a current ratio of 2.66, a quick ratio of 2.34 and a debt-to-equity ratio of 0.30.
Rewalk Robotics (NASDAQ:RWLK) last released its earnings results on Wednesday, November 13th. The medical device company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.01). Rewalk Robotics had a negative net margin of 322.41% and a negative return on equity of 192.14%. The firm had revenue of $1.23 million during the quarter, compared to analyst estimates of $3.27 million. Research analysts forecast that Rewalk Robotics will post -2.54 EPS for the current year.
A number of institutional investors have recently added to or reduced their stakes in RWLK. FNY Investment Advisers LLC raised its stake in Rewalk Robotics by 199.7% in the third quarter. FNY Investment Advisers LLC now owns 225,120 shares of the medical device company’s stock valued at $688,000 after purchasing an additional 150,000 shares in the last quarter. Sabby Management LLC raised its position in shares of Rewalk Robotics by 46.9% in the 3rd quarter. Sabby Management LLC now owns 115,000 shares of the medical device company’s stock worth $352,000 after acquiring an additional 36,700 shares in the last quarter. Finally, Barclays PLC lifted its position in Rewalk Robotics by 115,833.3% during the third quarter. Barclays PLC now owns 13,912 shares of the medical device company’s stock valued at $43,000 after buying an additional 13,900 shares during the period. Institutional investors and hedge funds own 9.20% of the company’s stock.
A number of research analysts have commented on the company. Zacks Investment Research lowered Rewalk Robotics from a “buy” rating to a “hold” rating in a report on Thursday. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 target price on shares of Rewalk Robotics in a report on Friday, November 15th. Finally, ValuEngine upgraded shares of Rewalk Robotics from a “hold” rating to a “buy” rating in a research report on Saturday, November 23rd.
Rewalk Robotics Company Profile
ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes exoskeletons for wheelchair-bound individuals with mobility impairments or other medical conditions. The company offers ReWalk Personal for everyday use to paraplegic individuals at home and in their communities; and ReWalk Rehabilitation for exercise and therapy used in hospitals and rehabilitation centers in the United States and Europe.
Featured Story: What is the float in trading stocks?
Receive News & Ratings for Rewalk Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rewalk Robotics and related companies with MarketBeat.com's FREE daily email newsletter.